Yubo International Biotech Ltd SEC filings YBGJ

Yubo International Biotech Ltd has 284 filings in SEC EDGAR's recent list, going back to May 29, 1996. Its latest annual report, Form ARS, was filed on Jun 12, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 14, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Jan 16, 2026 (auditor change). The company's fiscal year ends on December 31.

Yubo International Biotech Ltd SEC filings
Form Description Filed Period
ARS Annual report to shareholders Jun 12, 2026 Dec 31, 2025
10-K Annual report Mar 31, 2026 Dec 31, 2025
10-K Annual report Mar 31, 2025 Dec 31, 2024
10-K Annual report Apr 12, 2024 Dec 31, 2023
10-K Annual report Apr 14, 2023 Dec 31, 2022
10-K Annual report Apr 15, 2022 Dec 31, 2021
10-KT Transition report Apr 23, 2021 Dec 31, 2020
10-K Annual report Jun 25, 2020 Feb 29, 2020
10-K Annual report Jun 12, 2019 Feb 28, 2019
10-K Annual report Jun 13, 2018 Feb 28, 2018
10-K Annual report Jun 14, 2017 Feb 28, 2017
10-K Annual report Jun 10, 2016 Feb 29, 2016
10-K Annual report Jun 15, 2015 Feb 28, 2015
10-K Annual report Jun 6, 2014 Feb 28, 2014
10-K Annual report Jun 12, 2013 Feb 28, 2013
10-K Annual report Jun 11, 2012 Feb 29, 2012
10-K Annual report Jun 14, 2011 Feb 28, 2011
10-K Annual report Jun 16, 2010 Feb 28, 2010
10-K Annual report Jun 12, 2009 Feb 28, 2009

Showing 19 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.

Company profile

Industry
Electromedical & Electrotherapeutic Apparatus (SIC 3845)
Listed as
YBGJ (OTC)
Fiscal year ends
December 31
Incorporated in
NY
Headquarters
Beijing, China
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
895464
Former names
MAGNA LAB INC (until Dec 4, 2020)

Other Electromedical & Electrotherapeutic Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.